Soluble receptor for advanced glycation end products and the risk for incident heart failure

The Atherosclerosis Risk in Communities Study

Mariana Lazo-Elizondo, Marc K Halushka, Lu Shen, Nisa Maruthur, Casey Rebholz, Andreea M. Rawlings, Ron C. Hoogeveen, Tina E. Brinkley, Christie M. Ballantyne, Brad C. Astor, Elizabeth Selvin

Research output: Contribution to journalArticle

Abstract

Background Experimental studies in animals suggest that circulating soluble receptor for advanced glycation end products (sRAGE) decrease oxidative stress, inflammation, and fibrosis. The association between sRAGE and incident heart failure has not been systematically examined in a prospective study. Methods We conducted a prospective analysis of a subsample of 1,086 participants from the Atherosclerosis Risk in Communities Study who attended visit 2 (1990-1992) without a history of coronary heart disease, stroke, or heart failure and with measured plasma sRAGE levels. Incident heart failure was defined as death from heart failure or hospitalization due to heart failure during a median of 20 years of follow-up. Results In this sample of a community-based population (mean age 63 years, 60% women, 78% white), there were 126 incident cases of heart failure. Lower levels of sRAGE were significantly associated with an increased risk of heart failure; the adjusted hazard ratios (95% CIs) of heart failure were 1.0 (reference), 1.81 (0.94-3.49), 1.57 (0.80-3.08), and 3.37 (1.75-6.50), for fourth, third, second, and first quartiles, respectively (P for trend =.001). We did not observe significant interactions by diabetes status or by race or obesity status. Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.

Original languageEnglish (US)
Pages (from-to)961-967
Number of pages7
JournalAmerican Heart Journal
Volume170
Issue number5
DOIs
StatePublished - 2015

Fingerprint

Atherosclerosis
Heart Failure
Advanced Glycosylation End Product-Specific Receptor
Population
Coronary Disease
Hospitalization
Oxidative Stress
Fibrosis
Cardiovascular Diseases
Obesity
Stroke
Prospective Studies
Inflammation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Soluble receptor for advanced glycation end products and the risk for incident heart failure : The Atherosclerosis Risk in Communities Study. / Lazo-Elizondo, Mariana; Halushka, Marc K; Shen, Lu; Maruthur, Nisa; Rebholz, Casey; Rawlings, Andreea M.; Hoogeveen, Ron C.; Brinkley, Tina E.; Ballantyne, Christie M.; Astor, Brad C.; Selvin, Elizabeth.

In: American Heart Journal, Vol. 170, No. 5, 2015, p. 961-967.

Research output: Contribution to journalArticle

@article{428f58a5a8e046ba99782afe2490f416,
title = "Soluble receptor for advanced glycation end products and the risk for incident heart failure: The Atherosclerosis Risk in Communities Study",
abstract = "Background Experimental studies in animals suggest that circulating soluble receptor for advanced glycation end products (sRAGE) decrease oxidative stress, inflammation, and fibrosis. The association between sRAGE and incident heart failure has not been systematically examined in a prospective study. Methods We conducted a prospective analysis of a subsample of 1,086 participants from the Atherosclerosis Risk in Communities Study who attended visit 2 (1990-1992) without a history of coronary heart disease, stroke, or heart failure and with measured plasma sRAGE levels. Incident heart failure was defined as death from heart failure or hospitalization due to heart failure during a median of 20 years of follow-up. Results In this sample of a community-based population (mean age 63 years, 60{\%} women, 78{\%} white), there were 126 incident cases of heart failure. Lower levels of sRAGE were significantly associated with an increased risk of heart failure; the adjusted hazard ratios (95{\%} CIs) of heart failure were 1.0 (reference), 1.81 (0.94-3.49), 1.57 (0.80-3.08), and 3.37 (1.75-6.50), for fourth, third, second, and first quartiles, respectively (P for trend =.001). We did not observe significant interactions by diabetes status or by race or obesity status. Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.",
author = "Mariana Lazo-Elizondo and Halushka, {Marc K} and Lu Shen and Nisa Maruthur and Casey Rebholz and Rawlings, {Andreea M.} and Hoogeveen, {Ron C.} and Brinkley, {Tina E.} and Ballantyne, {Christie M.} and Astor, {Brad C.} and Elizabeth Selvin",
year = "2015",
doi = "10.1016/j.ahj.2015.08.008",
language = "English (US)",
volume = "170",
pages = "961--967",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",
number = "5",

}

TY - JOUR

T1 - Soluble receptor for advanced glycation end products and the risk for incident heart failure

T2 - The Atherosclerosis Risk in Communities Study

AU - Lazo-Elizondo, Mariana

AU - Halushka, Marc K

AU - Shen, Lu

AU - Maruthur, Nisa

AU - Rebholz, Casey

AU - Rawlings, Andreea M.

AU - Hoogeveen, Ron C.

AU - Brinkley, Tina E.

AU - Ballantyne, Christie M.

AU - Astor, Brad C.

AU - Selvin, Elizabeth

PY - 2015

Y1 - 2015

N2 - Background Experimental studies in animals suggest that circulating soluble receptor for advanced glycation end products (sRAGE) decrease oxidative stress, inflammation, and fibrosis. The association between sRAGE and incident heart failure has not been systematically examined in a prospective study. Methods We conducted a prospective analysis of a subsample of 1,086 participants from the Atherosclerosis Risk in Communities Study who attended visit 2 (1990-1992) without a history of coronary heart disease, stroke, or heart failure and with measured plasma sRAGE levels. Incident heart failure was defined as death from heart failure or hospitalization due to heart failure during a median of 20 years of follow-up. Results In this sample of a community-based population (mean age 63 years, 60% women, 78% white), there were 126 incident cases of heart failure. Lower levels of sRAGE were significantly associated with an increased risk of heart failure; the adjusted hazard ratios (95% CIs) of heart failure were 1.0 (reference), 1.81 (0.94-3.49), 1.57 (0.80-3.08), and 3.37 (1.75-6.50), for fourth, third, second, and first quartiles, respectively (P for trend =.001). We did not observe significant interactions by diabetes status or by race or obesity status. Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.

AB - Background Experimental studies in animals suggest that circulating soluble receptor for advanced glycation end products (sRAGE) decrease oxidative stress, inflammation, and fibrosis. The association between sRAGE and incident heart failure has not been systematically examined in a prospective study. Methods We conducted a prospective analysis of a subsample of 1,086 participants from the Atherosclerosis Risk in Communities Study who attended visit 2 (1990-1992) without a history of coronary heart disease, stroke, or heart failure and with measured plasma sRAGE levels. Incident heart failure was defined as death from heart failure or hospitalization due to heart failure during a median of 20 years of follow-up. Results In this sample of a community-based population (mean age 63 years, 60% women, 78% white), there were 126 incident cases of heart failure. Lower levels of sRAGE were significantly associated with an increased risk of heart failure; the adjusted hazard ratios (95% CIs) of heart failure were 1.0 (reference), 1.81 (0.94-3.49), 1.57 (0.80-3.08), and 3.37 (1.75-6.50), for fourth, third, second, and first quartiles, respectively (P for trend =.001). We did not observe significant interactions by diabetes status or by race or obesity status. Conclusions Lower circulating levels of sRAGE are independently associated with the development of heart failure in a community-based population. Our results add to the growing evidence that sRAGE is a valuable predictor of cardiovascular disease.

UR - http://www.scopus.com/inward/record.url?scp=84954270822&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954270822&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2015.08.008

DO - 10.1016/j.ahj.2015.08.008

M3 - Article

VL - 170

SP - 961

EP - 967

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

IS - 5

ER -